kabutan

BrightPath Biotherapeutics Co., Ltd.(4594) Summary

4594
TSE Growth
BrightPath Biotherapeutics Co., Ltd.
63
JPY
-2
(-3.08%)
Jan 29, 1:38 pm JST
0.41
USD
Jan 28, 11:38 pm EST
Result
PTS
outside of trading hours
63
Jan 29, 1:35 pm JST
Summary Chart Historical News Financial Result
PER
PBR
4.73
Yield
ー%
Margin Trading Ratio
6.24
Stock Price
Jan 29, 2026
Opening Jan 29, 9:00 am
65 JPY 0.42 USD
Previous Close Jan 28
65 JPY 0.42 USD
High Jan 29, 9:00 am
65 JPY 0.42 USD
Low Jan 29, 9:01 am
63 JPY 0.41 USD
Volume
2,521,700
Trading Value
0.16B JPY 1.05M USD
VWAP
63.7 JPY 0.42 USD
Minimum Trading Value
6,300 JPY 41 USD
Market Cap
7.12B JPY 0.05B USD
Number of Trades
311
Liquidity & Number of Trades
As of Jan 29, 2026
Liquidity
Slightly High
1-Year Average
626
1-Year High Aug 15, 2025
10,957
Margin Trading
Date Short Interest Long Margin Positions Ratio
Jan 23, 2026 1,655,200 18,110,200 10.94
Jan 16, 2026 1,407,300 11,139,900 7.92
Jan 9, 2026 1,418,800 11,146,300 7.86
Dec 26, 2025 1,418,800 11,619,400 8.19
Dec 19, 2025 1,418,800 12,939,800 9.12
Company Profile
BrightPath Biotherapeutics Co., Ltd. is a biotech venture originating from Kurume University, focusing on cancer immunotherapy using NKT cells and antibody drugs.
Sector
Pharmaceuticals
BrightPath Biotherapeutics Co., Ltd. is a drug discovery venture specializing in the development of cancer immunotherapy drugs, originating from Kurume University. The company has multiple pipelines ranging from exploratory research to early clinical trial stages, with a business model that generates revenue by licensing out to domestic and international pharmaceutical companies for late-stage clinical trials and beyond. Major development pipelines include iPS cell-derived NKT cell therapy, CAR-T cell therapy, antibody drugs, and personalized neoantigen vaccines. Notably, in the field of iPS cell-derived NKT cell therapy, the company exercised its option rights in November 2022 to acquire an exclusive development, manufacturing, and sales license from RIKEN, and is conducting the world's first clinical trial using iPS-NKT cells for head and neck cancer. Additionally, the company is advancing the development of CAR-T cell therapy for solid tumors. BrightPath Biotherapeutics is also developing antibody drugs targeting molecules that suppress cancer immunity, aiming to innovate cancer treatment through multiple approaches.